SEC Form 4 · accession 0000315066-15-002590
Blueprint Medicines Corp · BPMC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 5, 2015 | C | 1,818,181 | — | A | 1,818,181 | I | Beacon Bioventures Fund III Limited Partnership |
| Common StockF1,F2 | May 5, 2015 | C | 469,696 | — | A | 2,287,877 | I | Beacon Bioventures Fund III Limited Partnership |
| Common StockF1,F2 | May 5, 2015 | C | 87,834 | — | A | 2,375,711 | I | Beacon Bioventures Fund III Limited Partnership |
| Common StockF2 | May 5, 2015 | P | 125,000 | $18.00 | A | 2,500,711 | I | Beacon Bioventures Fund III Limited Partnership |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Convertible Preferred StockF1 | — | May 5, 2015 | C | 10,000,000 | A | — | — | Common Stock | 1,818,181 | 0 | I |
| Series B Convertible Preferred StockF1 | — | May 5, 2015 | C | 2,583,333 | A | — | — | Common Stock | 469,696 | 0 | I |
| Series C Convertible Preferred StockF1 | — | May 5, 2015 | C | 483,092 | A | — | — | Common Stock | 87,834 | 0 | I |
Explanation of responses
- F1On May 5, 2015, in connection with the completion of the issuer's initial public offering, all shares of Convertible Preferred Stock converted into Common Stock on a 5.5-for-1 basis.
- F2FMR Co., Inc. and Pyramis Global Advisors, LLC, each an indirect wholly-owned subsidiary of FMR LLC and an investment adviser registered under the Investment Advisers Act of 1940, and Pyramis Global Advisors Trust Company, an indirect wholly-owned subsidiary of FMR LLC and a bank as defined in Section 3(a)(6) of the Securities Exchange Act of 1934, are the beneficial owners of Common Stock of Blueprint Medicines Corp., as a result of acting as investment adviser to various investment companies registered under the Investment Company Act of 1940, institutional accounts and non-U.S. mutual funds. FMR LLC, Edward C. Johnson 3d and Abigail P. Johnson have no pecuniary interest in the Common Stock beneficially owned by FMR Co., Inc. and Pyramis Global Advisors, LLC and Pyramis Global Advisors Trust Company and Column 5 of Table I does not include such shares.
Remarks
Remark 1: Edward C. Johnson 3d is a Director and the Chairman of FMR LLC and Abigail P. Johnson is a Director, the Vice Chairman and the President of FMR LLC. Members of the family of Edward C. Johnson 3d, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Edward C. Johnson 3d and Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: Beacon Bioventures Advisors Fund III Limited Partnership is the general partner of Beacon Bioventures Fund III Limited Partnership. Beacon Bioventures Advisors Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the family of Edward C. Johnson 3d.